These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 26122820)

  • 41. Analysis of genetic alterations, classified according to their DNA ploidy pattern, in the progression of colorectal adenomas and early colorectal carcinomas.
    Sugai T; Takahashi H; Habano W; Nakamura S; Sato K; Orii S; Suzuki K
    J Pathol; 2003 Jun; 200(2):168-76. PubMed ID: 12754737
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Clinical-pathological features and gene profile in colorectal cancer].
    Perazzo F; Piaggio F; Krupitzki H; García A; Avagnina A; Elsner B; Denninghoff V
    Medicina (B Aires); 2013; 73(5):417-22. PubMed ID: 24152396
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Detection of chromosomal aberration using fluorescence in situ hybridization in DNA diploid colorectal carcinomas].
    Jibiki M; Tagawa Y; Miyashita K; Hara S; Yasutake T; Nakazaki T; Obatake M; Sawai T; Morinaga M; Akama F
    Gan To Kagaku Ryoho; 1993 Apr; 20(6):759-62. PubMed ID: 8489281
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Prognostic significance of DNA ploidy and proliferation in 309 colorectal carcinomas as determined by two-color multiparametric DNA flow cytometry.
    Zarbo RJ; Nakhleh RE; Brown RD; Kubus JJ; Ma CK; Mackowiak P
    Cancer; 1997 Jun; 79(11):2073-86. PubMed ID: 9179053
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Site-specific Differences in Colonic Adenocarcinoma: KRAS Mutations and High Tumor Budding Are More Frequent in Cecal Adenocarcinoma.
    Landau MA; Zhu B; Akwuole FN; Pai RK
    Am J Surg Pathol; 2018 Mar; 42(3):351-358. PubMed ID: 29240583
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The association of clinicopathological features and survival in colorectal cancer patients with kras mutation status.
    Akman T; Oztop I; Baskin Y; Unek IT; Demir N; Ellidokuz H; Yilmaz AU
    J Cancer Res Ther; 2016; 12(1):96-102. PubMed ID: 27072218
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Molecular characterization of mucinous ovarian tumours supports a stratified treatment approach with HER2 targeting in 19% of carcinomas.
    Anglesio MS; Kommoss S; Tolcher MC; Clarke B; Galletta L; Porter H; Damaraju S; Fereday S; Winterhoff BJ; Kalloger SE; Senz J; Yang W; Steed H; Allo G; Ferguson S; Shaw P; Teoman A; Garcia JJ; Schoolmeester JK; Bakkum-Gamez J; Tinker AV; Bowtell DD; Huntsman DG; Gilks CB; McAlpine JN
    J Pathol; 2013 Jan; 229(1):111-20. PubMed ID: 22899400
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Tumor oncogene (KRAS) status and risk of venous thrombosis in patients with metastatic colorectal cancer.
    Ades S; Kumar S; Alam M; Goodwin A; Weckstein D; Dugan M; Ashikaga T; Evans M; Verschraegen C; Holmes CE
    J Thromb Haemost; 2015 Jun; 13(6):998-1003. PubMed ID: 25809746
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Clinical relevance of KRAS-mutated subclones detected with picodroplet digital PCR in advanced colorectal cancer treated with anti-EGFR therapy.
    Laurent-Puig P; Pekin D; Normand C; Kotsopoulos SK; Nizard P; Perez-Toralla K; Rowell R; Olson J; Srinivasan P; Le Corre D; Hor T; El Harrak Z; Li X; Link DR; Bouché O; Emile JF; Landi B; Boige V; Hutchison JB; Taly V
    Clin Cancer Res; 2015 Mar; 21(5):1087-97. PubMed ID: 25248381
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Lack of Relationship Between Clinical Features and KRAS Mutations in Patients with Metastatic Colorectal Cancer.
    Ploquin A; Zerimech F; Escande F; Adenis A; Giraud C; Gasnault L; Bourgeois V; Desauw C; Hebbar M
    Anticancer Res; 2016 Aug; 36(8):4233-6. PubMed ID: 27466537
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A mutation spectrum that includes GNAS, KRAS and TP53 may be shared by mucinous neoplasms of the appendix.
    Hara K; Saito T; Hayashi T; Yimit A; Takahashi M; Mitani K; Takahashi M; Yao T
    Pathol Res Pract; 2015 Sep; 211(9):657-64. PubMed ID: 26160192
    [TBL] [Abstract][Full Text] [Related]  

  • 52. High BRAF Mutation Frequency and Marked Survival Differences in Subgroups According to KRAS/BRAF Mutation Status and Tumor Tissue Availability in a Prospective Population-Based Metastatic Colorectal Cancer Cohort.
    Sorbye H; Dragomir A; Sundström M; Pfeiffer P; Thunberg U; Bergfors M; Aasebø K; Eide GE; Ponten F; Qvortrup C; Glimelius B
    PLoS One; 2015; 10(6):e0131046. PubMed ID: 26121270
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Prognostic value of DNA ploidy patterns of colorectal adenocarcinoma.
    Lin JK; Chang SC; Yang SH; Jiang JK; Chen WC; Lin TC
    Hepatogastroenterology; 2003; 50(54):1927-32. PubMed ID: 14696434
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Correlation between DPYD gene variation and KRAS wild type status in colorectal cancer.
    Kleist B; Kempa M; Meurer T; Poetsch M
    J Clin Pathol; 2016 Mar; 69(3):204-8. PubMed ID: 26281864
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Gene amplification of CCNE1, CCND1, and CDK6 in gastric cancers detected by multiplex ligation-dependent probe amplification and fluorescence in situ hybridization.
    Ooi A; Oyama T; Nakamura R; Tajiri R; Ikeda H; Fushida S; Dobashi Y
    Hum Pathol; 2017 Mar; 61():58-67. PubMed ID: 27864121
    [TBL] [Abstract][Full Text] [Related]  

  • 56. In depth evaluation of the prognostic and predictive utility of PTEN immunohistochemistry in colorectal carcinomas: performance of three antibodies with emphasis on intracellular and intratumoral heterogeneity.
    Ágoston EI; Micsik T; Ács B; Fekete K; Hahn O; Baranyai Z; Dede K; Bodoky G; Bursics A; Kulka J; Krenács T; Győrffy B; Harsányi L; Szász AM
    Diagn Pathol; 2016 Jul; 11(1):61. PubMed ID: 27392434
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Loss of CDX2 expression is associated with poor prognosis in colorectal cancer patients.
    Bae JM; Lee TH; Cho NY; Kim TY; Kang GH
    World J Gastroenterol; 2015 Feb; 21(5):1457-67. PubMed ID: 25663765
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Clinicopathological, immunohistochemical, and mutational analyses of pulmonary enteric adenocarcinoma: usefulness of SATB2 and β-catenin immunostaining for differentiation from metastatic colorectal carcinoma.
    Matsushima J; Yazawa T; Suzuki M; Takahashi Y; Ota S; Nakajima T; Yoshino I; Yokose T; Inoue T; Kawahara K; Nakatani Y
    Hum Pathol; 2017 Jun; 64():179-185. PubMed ID: 28438615
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Comparison of fluorescence in situ hybridization and flow cytometric DNA ploidy analysis in paraffin-embedded prostatic adenocarcinoma specimens.
    Lifson B; Pizzolo JG; Elhosseiny AA; Choudhury MS; Melamed MR
    Anal Quant Cytol Histol; 1995 Apr; 17(2):93-9. PubMed ID: 7542002
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Association Between Computed Tomographic Features and Kirsten Rat Sarcoma Viral Oncogene Mutations in Patients With Stage I Lung Adenocarcinoma and Their Prognostic Value.
    Wang H; Schabath MB; Liu Y; Stringfield O; Balagurunathan Y; Heine JJ; Eschrich SA; Ye Z; Gillies RJ
    Clin Lung Cancer; 2016 Jul; 17(4):271-8. PubMed ID: 26712103
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.